Nevro received FDA approval for an AI-powered, personalised pain management platform for spinal cord stimulation. HFX AdaptivAI, a responsive, personalised pain management platform, powers the HFX iQ spinal cord stimulation (SCS) system. The Redwood City, California-based company kicked off a limited market release of the offering following this approval. It originally launched the HFX iQ system in March 2023.
The company plans for a full market release in the U.S. in the fourth quarter of 2024.
Related: FDA approves study of Alpha Tau’s Alpha DaRT for recurrent cSCC treatment
Nevro says its HFX AdaptivAI is the only technology with AI for providing patients suffering from chronic pain with “an unprecedented level of personalized, responsive pain relief.”
The launch comes at a time of uncertainty for Nevro, which last month said it began looking into strategic alternatives amid increased competition in the SCS market.
“Nevro is further establishing its position as the leading developer of data-driven solutions for pain management through the launch of HFX iQ with HFX AdaptivAI,” said Kevin Thornal, Nevro’s CEO and president. “HFX AdaptivAI delivers personalized pain relief, utilizing AI and leveraging millions of data points and ten years of innovation and patient care. We believe this new solution is a major milestone, and it demonstrates our dedication to freeing patients from the burden of chronic pain through evidence-based therapies that transform patients’ lives.
“Importantly, HFX AdaptivAI puts patients in control of their pain relief while, at the same time, providing physicians the ability to monitor their patient’s pain journey – closing the loop that matters.”
